Indaptus Therapeutics is trading at $1.09 (+5.83%) now after releasing second-quarter 2026 results on August 13, 2026, which showed net loss narrowed to approximately $1.8 million from $5.2 million.
- Operating expenses declined substantially.
- Decoy20 enrollment remains discontinued, with no active clinical programs.
- The company announced a strategic review and new neurological-disorders research collaboration.